Also a big shout-out to the @theNCI Urologic Oncology (SUO) fellowship 🙌 The fellowship gives us a platform not just to sharpen our operating, but to rethink GU cancer as a biology and a disease process. It also trains us to make careful, multidisciplinary decisions for every patient. NCI is a remarkable place to learn to think as a surgeon-scientist. Our clinical year has been just as rewarding. We now rotate at Walter Reed, Sibley, GW, and MedStar Washington Hospital Center, which gives us broad exposure across the DC area. Interested Applicants feel free to DM with questions! @PeterPintoMD @markballmd @patmichael93 @ztonysu @Moh_AhmedMD @Anis_Assad10 @RubenBlachmanMD @SUO_YUO @UroOnc #SUO #YUO #UroSoMe

Grateful for the chance to work on this unique project and share our experience. Big shout-out to the @theNCI @SUO_YUO @UroOnc fellowship — outstanding mentors, co-fellows, supportive staff, and a great city. Doing science and having fun. 🙌 @markballmd

New paper out in @EurUrolOncol! 🧬 We present the largest prospective cohort of sporadic bilateral/multifocal papillary RCC (89 patients, 25 years at the NCI). Key findings: 📉 Slow, indolent growth (median 1.55 mm/yr) 🎯 No metastases when largest tumor <3cm 🔬 Low metastatic rate overall (6.7%) 🩺 Repeat ipsilateral partial nephrectomy = biggest hit to kidney function Supports active surveillance for small renal masses + nephron-sparing surgery when intervention is needed. @markballmd @RubenBlachmanMD @MillanBraden @patmichael93 Natural History, Tumor Growth Kinetics, and Renal Functional Outcomes... sciencedirect.com/science/ar…